# Editorial expression of concern: ERRα suppression enhances the cytotoxicity of the MEK inhibitor trametinib against colon cancer cells

**Authors:** Sheng Zhou, Hongwei Xia, Huanji Xu, Qiulin Tang, Yongzhan Nie, Qi Yong Gong, Feng Bi

PMC · DOI: 10.1186/s13046-025-03507-3 · 2025-08-15

## Full-text entities

- **Genes:** MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, EIF2AK3 (eukaryotic translation initiation factor 2 alpha kinase 3) [NCBI Gene 9451] {aka PEK, PERK, WRS}, ESRRA (estrogen related receptor alpha) [NCBI Gene 2101] {aka ERR1, ERRa, ERRalpha, ESRL1, NR3B1}, MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609] {aka JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}
- **Diseases:** cytotoxicity (MESH:D064420), colon cancer (MESH:D015179)
- **Chemicals:** trametinib (MESH:C560077)
- **Cell lines:** SW480 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0546), S2a — Drosophila melanogaster (Fruit fly), Spontaneously immortalized cell line (CVCL_Z232), HCT116 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_0291)

---
Source: https://tomesphere.com/paper/PMC12355848